HPDA-based tubule-targeting nanoplatform alleviates oxidative stress and ferroptosis for the reversal of renal interstitial fibrosis Authors: Zheng Xiao, Peng Luo, Guoli Li, Huifang Tan, Chen Zhou, Dong Zeng, Yinyin Chen, Ying Li Published: 2025 ABSTRACT BackgroundRenal interstitial fibrosis (RIF) is a hallmark pathological process in the progression of chronic kidney disease (CKD). However, effective therapies to halt or reverse RIF remain limited. Emerging evidence implicates ferroptosis as a critical contributor to RIF. Rosiglitazone (Rosi), a widely used thiazolidinedione, exhibits anti-ferroptotic activity but suffers from poor aqueous solubility, limited renal specificity, and systemic side effects.ResultsHere, we constructed a renal tubular epithelial cell-targeted nano-based drug delivery system—Rosi-loaded, K3 peptide–modified, PEGylated hollow polydopamine(HPDA) nanoparticles (Rosi@HPDA-PEG-K3 NPs). This system displayed excellent biocompatibility and lesion-specific targeting, achieving prolonged retention in fibrotic kidneys. The in vitro and in vivo experiment demonstrated that this nano-based drug delivery system inhibited ferroptosis through downregulation of ACSL4, iron ion chelation, and ROS scavenging. Concurrently, it stabilized mitochondrial membrane potential and synergistically suppressed inflammatory responses, ultimately attenuating RIF.ConclusionsIn summary, Rosi@HPDA-PEG-K3 NPs deliver Rosi specifically to renal renal tubular epithelial cells(TECs)and exert an anti-RIF effect through the integration of ferroptosis inhibition, mitochondrial protection, and inflammation modulation. Our study establishes a nanotherapeutic platform with precise targeting and multifunctional efficacy, highlighting its scientific rigor and the clinical translational potential of RIF.Graphical Abstract Synthesis of Rosi@HPDA-PEG-K3 nanoparticles and their targeted modulation of ferroptosis to suppress oxidative stress and inflammation amplification, thereby delaying or reversing renal interstitial fibrosis. Supplementary InformationThe online version contains supplementary material available at 10.1186/s12951-025-03927-5. Background Renal interstitial fibrosis (RIF) is primarily characterized by injury to tubular epithelial cells (TECs), abnormal fibroblast activation, and excessive extracellular matrix (ECM) deposition [1]. It serves as a final common pathological outcome in the progression of various chronic kidney diseases (CKD) to end-stage renal disease (ESRD) [2]. However, current clinical therapies to specifically and effectively prevent or reverse RIF remain limited. Consequently, there is a pressing need to develop innovative, effective, and precisely targeted anti-fibrotic strategies. TECs, as primary responders to renal injury, play a central role in driving RIF by undergoing stress-induced dysfunction and death [3]. Among the various forms of regulated cell death, ferroptosis—characterized by iron overload, lipid peroxidation, and redox imbalance—has recently emerged as a key driver of tubular injury and fibrosis [4–6]. Furthermore, ferroptosis contributes to a self-amplifying loop of oxidative stress, mitochondrial dysfunction, and inflammation via activation of the NLRP3 inflammasome [7]. Accumulating evidence indicates that pharmacological inhibition of ferroptosis significantly alleviates renal fibrosis in multiple chronic kidney disease (CKD) models, including unilateral ureteral obstruction (UUO), 5/6 nephrectomy, folic acid nephropathy, and ischemia/reperfusion injury [8–11]. Among these, the UUO model is the most widely used and well-established experimental system for mechanistic and therapeutic evaluation of renal fibrosis due to its reproducibility and controlled progression [12, 13]. Collectively, these findings highlight ferroptosis as a promising therapeutic target in CKD and underscore the potential of ferroptosis-modulating therapies for antifibrotic intervention. Acyl-CoA synthetase long-chain family member 4 (ACSL4) is a key regulator of ferroptosis that facilitates the esterification of polyunsaturated fatty acids (PUFAs) into membrane phospholipids, thereby increasing cellular susceptibility to lipid peroxidation [14, 15]. Research shows that genetic knockdown or pharmacological inhibition of ACSL4 significantly reduces ferroptosis sensitivity [14]. Rosiglitazone (Rosi), as the only compound in the thiazolidinedione class of drugs that specifically inhibits ACSL4 activity, has been widely used in ferroptosis-related studies [16]. Prior studies have demonstrated that Rosi can alleviate renal injury and delay fibrosis progression in UUO, and folic acid models by suppressing ACSL4-mediated ferroptosis [14, 17]. However, the clinical application of Rosi is limited by its poor solubility, low bioavailability, broad tissue distribution, short circulatory half-life, as well as its potential adverse effects, including cardiovascular events, bone fractures, and bladder cancer [18–21]. Hollow polydopamine nanoparticles (HPDA), featuring excellent biocompatibility, biodegradability, and a high density of phenolic hydroxyl groups, exhibit intrinsic capabilities for reactive oxygen species (ROS) scavenging and Fe²⁺ chelation—both of which align with key ferroptosis regulatory targets [22–26]. In addition, the hollow architecture of HPDA enables efficient encapsulation of small-molecule drugs and functionalization with targeting ligands, offering versatile therapeutic capabilities. Specifically, the K3 peptide—a specific ligand for TECs, binds to megalin receptors and facilitates active, cell-specific delivery [27]. Accordingly, a multifunctional nanodrug delivery system—Rosi@HPDA-PEG-K3 nanoparticles (NPs)—was developed, integrating iron chelation, antioxidative, anti-ferroptosis, and targeted delivery features. The antifibrotic efficacy of this platform was comprehensively evaluated in vitro and in vivo, and its underlying mechanisms were elucidated with a focus on ferroptosis suppression, mitochondrial protection, and inflammation modulation. This work provides a promising strategy and mechanistic basis for precision anti-fibrotic therapy in CKD. Methods Reagents and materials Tetraethyl orthosilicate (TEOS), Rosi, and ABTS solution were obtained from Aladdin Biochemical Technology Co., Ltd (Shanghai, China). NH₂-PEG-NH₂, and pyrogallol solution were purchased from Titan Scientific Co., Ltd., (Shanghai, China). K3 peptide solution were obtained from Shenggong Bioengineering Co., Ltd (Shanghai, China). α-SMA (cat.no.14395-1-AP), ACSL4(cat.no.22401-1-AP), and GPX4(cat.no.67763-1-Ig) antibodies were obtained from Proteintech (Chicago, USA). Fibronectin (Fn, cat.no.ab2413) antibodies were obtained from Abcam (Cambridge, UK). Collagen I (Col-I, cat.no.AF7001) antibodies were obtained from Affinity Biosciences (Jiangsu, China). 4-HNE (cat.no.BS-6313R) antibodies were purchased from Bioss (Beijing, China). Secondary antibody and DAB chromogen were purchased from Zsbio (Beijing, China) or Proteintech (Chicago, USA). Cy5.5 were purchased from Macklin (Shanghai, China). Dulbecco’s Modified Eagle Medium (DMEM) were purchased from Gibco (Waltham, MA, USA). Fetal bovine serum (FBS) were purchased from Biological Industries (Cromwell, CT, USA). TGF-β1 were purchased from Sino Biological Inc. (Beijing, China). CCK8 kit, Dihydroethidium (DHE) kit, Dichlorodihydrofluorescein diacetate (DCFH-DA) kit, MitoSOX™ Red kit, and JC-1 Staining were purchased from Beyotime (Shanghai, China). Enhanced chemiluminescence (ECL) detection kit were purchased from Thermo Scientific (Massachusetts, USA). SOD, GSH, and MDA detection kit were purchased from Nanjing Jiancheng Bioengineering Institute (Nanjing, China). ELISA kits were purchased from R&D Systems (Minneapolis, MN, USA). Synthesis of Rosi@HPDA-PEG-K3 NPs Synthesis of HPDA A mixture of 74 mL anhydrous ethanol, 10 mL deionized water, and 3.14 mL ammonia solution (25–28%, w/w) was stirred for 5 min. Then, 3.20 mL of tetraethyl orthosilicate (TEOS; Aladdin Biochemical Technology Co., Ltd., Shanghai, China) was added and the solution was stirred for 1 h to form dense silica (dSiO₂) nanoparticles. The obtained nanoparticles (5 mL) were resuspended in 30 mL Tris buffer (10 mM, pH 8.5), and 2 mL dopamine solution (75 mg/mL) was rapidly added. The suspension was stirred for 9 h to form dSiO₂@PDA nanoparticles. Subsequently, these particles were etched in a mixture of 15 mL ultrapure water, 15 mL ethanol, and 6 mL hydrofluoric acid (30% v/v) for 9.5 h at room temperature to remove the silica core. The hollow PDA (HPDA) nanoparticles were collected by centrifugation and washed thoroughly with deionized water. Rosi loading into HPDA 10 mg Rosi (R129769, Aladdin Biochemical Technology Co., Ltd., Shanghai, China) was dissolved in 5 mL water and added under ultrasonication to 10 mL of HPDA dispersion (1 mg/mL). The mixture was stirred at room temperature for 6 h. The resulting HPDA@Rosi nanoparticles were collected by centrifugation at 16,000 rpm (~ 24,000 × g) for 30 min using a TGL-16 high-speed centrifuge (Jintan Wenhua Instruments, China), and the supernatant was discarded after centrifugation. The pellet was resuspended in 10 mL deionized water, sonicated for 5 min to achieve uniform dispersion, and centrifuged at 16,000 rpm (~ 24,000 × g) for 10 min. This washing step was repeated three times. After the third wash, the supernatant exhibited a UV–Vis absorbance < 0.05 at 318 nm, confirming the complete removal of free Rosi. The purified nanoparticles were resuspended in PBS (pH 7.4) and stored at 4 °C for subsequent use. Synthesis of Rosi@HPDA-PEG The purified HPDA@Rosi nanoparticles were resuspended in deionized water, and the pH was adjusted to 10 with NaOH to facilitate PEGylation. Then, 250 µL of NH₂–PEG–NH₂ solution (60 mg/mL; Titan Scientific Co., Ltd., Shanghai, China) was added dropwise under continuous stirring for 24 h. The PEGylated nanoparticles (Rosi@HPDA-PEG) were collected by centrifugation and washed twice with deionized water. Synthesis of Rosi@HPDA-PEG-K3 K3 peptide was conjugated to PEG-terminal amines on Rosi@HPDA-PEG nanoparticles via EDC/NHS-mediated amide coupling. Briefly, EDC·HCl (10 mg, 0.052 mmol) and NHS (5 mg, 0.043 mmol) were added to 0.20 mL of K3 peptide solution (1 mg/mL; Shenggong Bioengineering Co., Ltd., Shanghai, China) in MES buffer (0.1 M, pH 5.5) and stirred for 20 min to activate carboxyl groups through NHS ester formation. The activated K3 was then added to a Rosi@HPDA-PEG dispersion (2 mL, 5 mg/mL) in HEPES buffer (10 mM, pH 7.4) and stirred for 36 h to enable covalent linkage with PEG-terminal amines. The molar ratio of PEG–NH₂ : EDC : NHS : K3 was 1 : 10 : 10 : 0.2, with surface amines quantified by TNBS assay. The product was purified by dialysis (MWCO 10 kDa) against deionized water for 48 h (water refreshed every 6–8 h), followed by centrifugation at 16,000 rpm (~ 24,000 × g) for 15 min and three washes with deionized water to remove unreacted components, yielding the final Rosi@HPDA-PEG-K3 nanoparticles. Characterization The morphology of Rosi@HPDA-PEG-K3 nanoparticles was characterized by high-resolution transmission electron microscopy (HRTEM; Philips, The Netherlands). Particle size distribution and zeta potential were measured using a dynamic light scattering (DLS) system (Zetasizer Nano ZS90; Malvern Instruments, UK). The UV–Vis absorption spectra of Rosi, HPDA, PEG, and K3 were obtained using an N4S UV–Vis spectrophotometer (Shanghai INESA Analytical Instrument Co., Ltd., China) scanned from 200 to 800 nm with a 1 nm resolution. Drug release Rosi@HPDA-PEG-K3 NPs (30 mg) were dispersed in 30 mL PBS (0.5% Tween 80) and loaded into dialysis bags. Bags were dialyzed at 37 °C in PBS (pH 7.4, 6.5, or 5.5; 100 mL). At set intervals, 2 mL of medium was collected and replaced. Samples were lyophilized, redissolved in water and DMSO, and analyzed by HPLC. Data represent three independent experiments. ROS and superoxide anion (O₂•⁻) scavenging assays ROS scavenging assay ABTS•⁺ solution was prepared by mixing ABTS (7.4 mM) and K₂S₂O₈ (2.6 mM), incubated in the dark for 12 h, and diluted 50-fold with ethanol. Absorbance at 734 nm was measured after mixing 1.6 mL of ABTS solution with 0.6 mL ethanol (A₀) or HPDA-PEG-K3 NPs at various concentrations (A). \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\text{Scavenging Rate}=[(\text{Ao - Ao}/\mathrm{Ao}]\times100$$\end{document} O₂•⁻ scavenging assay HPDA-PEG-K3 solutions of varying concentrations were added to 4 mL Tris-HCl buffer (0.05 M, pH 8.2), followed by 1 mL pyrogallol (0.2 mM). After reacting at 25 °C for 4 min, the reaction was stopped with concentrated HCl. Absorbance at 325 nm was recorded (A_sample). Distilled water was used as the blank (A_blank). Scavenging rate (%) = [(A_blank − A_sample)/A_blank] × 100. Determination of iron content Fe²⁺ levels in kidney tissue and HK-2 cells were determined using a commercial iron assay kit (MAK472, Sigma–Aldrich, St. Louis, MO, USA). Kidney samples were homogenized with a tissue grinder, while cells were harvested and lysed via ultrasonic disruption. Supernatants were collected according to the manufacturer’s instructions and analyzed at 593 nm using a microplate reader. Animal studies Male C57BL/6 mice (8–12 weeks old, 20–25 g) were purchased from Slack Jingda Experimental Animal Co., Ltd. (Hunan, China) and housed in the SPF animal room with free access to food and water. All experimental procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of Hunan Provincial People’s Hospital (No. 2024114). Biocompatibility study: Normal male C57BL/6 mice were randomly divided into two groups (n = 5 per group) and intravenously injected with either PBS or Rosi@HPDA-PEG-K3. Mice were sacrificed at 2 h and on days 1, 7, and 14 post-injection. Major organs, including the heart, liver, spleen, lungs, and kidneys, were harvested for histological analysis. Blood samples were collected for hematological evaluation and assessment of liver and kidney function biomarkers. Construction of the UUO model: The UUO model was established under anesthesia with intraperitoneal injection of pentobarbital sodium. After exposing the left kidney, the ureter was double-ligated and transected between the ligatures [28, 29]. In the Sham group, the ureter was isolated without ligation. In vivo Biodistribution: Cy5.5-labeled Rosi@HPDA and Rosi@HPDA-PEG-K3 nanoparticles were prepared for in vivo biodistribution analysis. UUO mice were intravenously injected via tail-vein injection (i.v.) with 200 µL of Cy5.5-labeled nanoparticles at a Rosi-equivalent dose of 10 mg/kg (single administration). Mice were sacrificed at 2 h, and on days 1, 7, and 14 post-injection. Prior to organ collection, all animals were transcardially perfused with 10 mL of cold PBS to remove circulating nanoparticles. Major organs (heart, liver, spleen, lung, and kidney) were harvested for ex vivo fluorescence imaging using a multifunctional imaging system (Fusion FX7; Vilber Lourmat, USA). Experimental Group: Mice were randomly assigned into five groups (n = 5 per group): Sham, UUO, UUO + Rosi, UUO + HPDA, UUO + Rosi@HPDA, UUO + HPDA@PEG-K3, and UUO + Rosi@HPDA-PEG-K3. Rosi, HPDA, Rosi@HPDA, HPDA@PEG-K3, and Rosi@HPDA-PEG-K3 NPs were administered i.v. via the tail vein at a Rosi-equivalent dose of 10 mg/kg in a 200 µL volume, as previously described [30]. Prophylactic administration commenced one day prior to UUO surgery. The mice were sacrificed after 7 days, and the kidney was collected and cleaned with PBS. Hematoxylin and Eosin (HE) Staining and Masson’s Trichrome Staining: HE staining: Paraffin-embedded kidney sections were stained with hematoxylin and eosin (H&E) and examined under a light microscope. Tubular atrophy was scored on a scale of 0–4 based on the percentage of damaged tubulointerstitial area: 0 (no damage), 1 (< 25%), 2 (25–50%), 3 (50–75%), and 4 (> 75%). At least 6 randomly selected fields per mouse were analyzed (n = 5 per group). Masson’s trichrome staining: Kidney sections were stained using Masson’s trichrome method to evaluate interstitial fibrosis. Collagen deposition was quantified using Image-Pro Plus 6.0 software across ≥ 6 randomly selected fields per mouse (n = 5 per group). Immunohistochemistry: Kidney sections were deparaffinized, subjected to antigen retrieval in 0.1 M sodium citrate buffer (pH 6.0), and blocked with normal goat serum. Primary antibodies against α-SMA (Proteintech, 14395-1-AP, 1:2000), Fn (Abcam, #ab2413, 1:200), and 4-HNE (Bioss Antibodies, BS-6313R, 1:100) were applied and incubated overnight at 4 °C. Negative controls were treated with normal serum. Following secondary antibody incubation and DAB chromogenic reaction, immunohistochemical analysis was performed using a Nikon microscope. Protein expression was quantified as the percentage of positively stained areas in at least six randomly selected fields per mouse using Image-Pro Plus 6.0 software. Male C57BL/6 mice (8–12 weeks old, 20–25 g) were purchased from Slack Jingda Experimental Animal Co., Ltd. (Hunan, China) and housed in the SPF animal room with free access to food and water. All experimental procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of Hunan Provincial People’s Hospital (No. 2024114). Male C57BL/6 mice (8–12 weeks old, 20–25 g) were purchased from Slack Jingda Experimental Animal Co., Ltd. (Hunan, China) and housed in the SPF animal room with free access to food and water. All experimental procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of Hunan Provincial People’s Hospital (No. 2024114). Biocompatibility study: Normal male C57BL/6 mice were randomly divided into two groups (n = 5 per group) and intravenously injected with either PBS or Rosi@HPDA-PEG-K3. Mice were sacrificed at 2 h and on days 1, 7, and 14 post-injection. Major organs, including the heart, liver, spleen, lungs, and kidneys, were harvested for histological analysis. Blood samples were collected for hematological evaluation and assessment of liver and kidney function biomarkers. Biocompatibility study: Normal male C57BL/6 mice were randomly divided into two groups (n = 5 per group) and intravenously injected with either PBS or Rosi@HPDA-PEG-K3. Mice were sacrificed at 2 h and on days 1, 7, and 14 post-injection. Major organs, including the heart, liver, spleen, lungs, and kidneys, were harvested for histological analysis. Blood samples were collected for hematological evaluation and assessment of liver and kidney function biomarkers. Construction of the UUO model: The UUO model was established under anesthesia with intraperitoneal injection of pentobarbital sodium. After exposing the left kidney, the ureter was double-ligated and transected between the ligatures [28, 29]. In the Sham group, the ureter was isolated without ligation. Construction of the UUO model: The UUO model was established under anesthesia with intraperitoneal injection of pentobarbital sodium. After exposing the left kidney, the ureter was double-ligated and transected between the ligatures [28, 29]. In the Sham group, the ureter was isolated without ligation. In vivo Biodistribution: Cy5.5-labeled Rosi@HPDA and Rosi@HPDA-PEG-K3 nanoparticles were prepared for in vivo biodistribution analysis. UUO mice were intravenously injected via tail-vein injection (i.v.) with 200 µL of Cy5.5-labeled nanoparticles at a Rosi-equivalent dose of 10 mg/kg (single administration). Mice were sacrificed at 2 h, and on days 1, 7, and 14 post-injection. Prior to organ collection, all animals were transcardially perfused with 10 mL of cold PBS to remove circulating nanoparticles. Major organs (heart, liver, spleen, lung, and kidney) were harvested for ex vivo fluorescence imaging using a multifunctional imaging system (Fusion FX7; Vilber Lourmat, USA). In vivo Biodistribution: Cy5.5-labeled Rosi@HPDA and Rosi@HPDA-PEG-K3 nanoparticles were prepared for in vivo biodistribution analysis. UUO mice were intravenously injected via tail-vein injection (i.v.) with 200 µL of Cy5.5-labeled nanoparticles at a Rosi-equivalent dose of 10 mg/kg (single administration). Mice were sacrificed at 2 h, and on days 1, 7, and 14 post-injection. Prior to organ collection, all animals were transcardially perfused with 10 mL of cold PBS to remove circulating nanoparticles. Major organs (heart, liver, spleen, lung, and kidney) were harvested for ex vivo fluorescence imaging using a multifunctional imaging system (Fusion FX7; Vilber Lourmat, USA). Experimental Group: Mice were randomly assigned into five groups (n = 5 per group): Sham, UUO, UUO + Rosi, UUO + HPDA, UUO + Rosi@HPDA, UUO + HPDA@PEG-K3, and UUO + Rosi@HPDA-PEG-K3. Rosi, HPDA, Rosi@HPDA, HPDA@PEG-K3, and Rosi@HPDA-PEG-K3 NPs were administered i.v. via the tail vein at a Rosi-equivalent dose of 10 mg/kg in a 200 µL volume, as previously described [30]. Prophylactic administration commenced one day prior to UUO surgery. The mice were sacrificed after 7 days, and the kidney was collected and cleaned with PBS. Experimental Group: Mice were randomly assigned into five groups (n = 5 per group): Sham, UUO, UUO + Rosi, UUO + HPDA, UUO + Rosi@HPDA, UUO + HPDA@PEG-K3, and UUO + Rosi@HPDA-PEG-K3. Rosi, HPDA, Rosi@HPDA, HPDA@PEG-K3, and Rosi@HPDA-PEG-K3 NPs were administered i.v. via the tail vein at a Rosi-equivalent dose of 10 mg/kg in a 200 µL volume, as previously described [30]. Prophylactic administration commenced one day prior to UUO surgery. The mice were sacrificed after 7 days, and the kidney was collected and cleaned with PBS. Hematoxylin and Eosin (HE) Staining and Masson’s Trichrome Staining: HE staining: Paraffin-embedded kidney sections were stained with hematoxylin and eosin (H&E) and examined under a light microscope. Tubular atrophy was scored on a scale of 0–4 based on the percentage of damaged tubulointerstitial area: 0 (no damage), 1 (< 25%), 2 (25–50%), 3 (50–75%), and 4 (> 75%). At least 6 randomly selected fields per mouse were analyzed (n = 5 per group). Masson’s trichrome staining: Kidney sections were stained using Masson’s trichrome method to evaluate interstitial fibrosis. Collagen deposition was quantified using Image-Pro Plus 6.0 software across ≥ 6 randomly selected fields per mouse (n = 5 per group). Hematoxylin and Eosin (HE) Staining and Masson’s Trichrome Staining: HE staining: Paraffin-embedded kidney sections were stained with hematoxylin and eosin (H&E) and examined under a light microscope. Tubular atrophy was scored on a scale of 0–4 based on the percentage of damaged tubulointerstitial area: 0 (no damage), 1 (< 25%), 2 (25–50%), 3 (50–75%), and 4 (> 75%). At least 6 randomly selected fields per mouse were analyzed (n = 5 per group). Masson’s trichrome staining: Kidney sections were stained using Masson’s trichrome method to evaluate interstitial fibrosis. Collagen deposition was quantified using Image-Pro Plus 6.0 software across ≥ 6 randomly selected fields per mouse (n = 5 per group). Immunohistochemistry: Kidney sections were deparaffinized, subjected to antigen retrieval in 0.1 M sodium citrate buffer (pH 6.0), and blocked with normal goat serum. Primary antibodies against α-SMA (Proteintech, 14395-1-AP, 1:2000), Fn (Abcam, #ab2413, 1:200), and 4-HNE (Bioss Antibodies, BS-6313R, 1:100) were applied and incubated overnight at 4 °C. Negative controls were treated with normal serum. Following secondary antibody incubation and DAB chromogenic reaction, immunohistochemical analysis was performed using a Nikon microscope. Protein expression was quantified as the percentage of positively stained areas in at least six randomly selected fields per mouse using Image-Pro Plus 6.0 software. Immunohistochemistry: Kidney sections were deparaffinized, subjected to antigen retrieval in 0.1 M sodium citrate buffer (pH 6.0), and blocked with normal goat serum. Primary antibodies against α-SMA (Proteintech, 14395-1-AP, 1:2000), Fn (Abcam, #ab2413, 1:200), and 4-HNE (Bioss Antibodies, BS-6313R, 1:100) were applied and incubated overnight at 4 °C. Negative controls were treated with normal serum. Following secondary antibody incubation and DAB chromogenic reaction, immunohistochemical analysis was performed using a Nikon microscope. Protein expression was quantified as the percentage of positively stained areas in at least six randomly selected fields per mouse using Image-Pro Plus 6.0 software. Cell studies HK-2 cells (ATCC, USA) were cultured in DMEM/F12 (Gibco, USA) with 10% FBS (Biological Industries, USA) and 1% penicillin-streptomycin (Gibco, USA) at 37 °C in a humidified atmosphere containing 5% CO₂. After 12 h of starvation using DMEM/F12 containing 0.5% FBS, HK-2 cells were treated with 10ng/ml TGF-β1 for 24 h. 100 µM Rosi and formulations treated cells for 24 h.Cell Viability Assay Cell viability was assessed using a CCK-8 kit (Beyotime, China). HK-2 cells were seeded in 96-well plates (1,000 cells/well), treated, and incubated with CCK-8 solution for 4 h. Absorbance was measured at 450 nm. HK-2 cells (ATCC, USA) were cultured in DMEM/F12 (Gibco, USA) with 10% FBS (Biological Industries, USA) and 1% penicillin-streptomycin (Gibco, USA) at 37 °C in a humidified atmosphere containing 5% CO₂. After 12 h of starvation using DMEM/F12 containing 0.5% FBS, HK-2 cells were treated with 10ng/ml TGF-β1 for 24 h. 100 µM Rosi and formulations treated cells for 24 h. HK-2 cells (ATCC, USA) were cultured in DMEM/F12 (Gibco, USA) with 10% FBS (Biological Industries, USA) and 1% penicillin-streptomycin (Gibco, USA) at 37 °C in a humidified atmosphere containing 5% CO₂. After 12 h of starvation using DMEM/F12 containing 0.5% FBS, HK-2 cells were treated with 10ng/ml TGF-β1 for 24 h. 100 µM Rosi and formulations treated cells for 24 h. Cell Viability Assay Cell viability was assessed using a CCK-8 kit (Beyotime, China). HK-2 cells were seeded in 96-well plates (1,000 cells/well), treated, and incubated with CCK-8 solution for 4 h. Absorbance was measured at 450 nm. Cell Viability Assay Cell viability was assessed using a CCK-8 kit (Beyotime, China). HK-2 cells were seeded in 96-well plates (1,000 cells/well), treated, and incubated with CCK-8 solution for 4 h. Absorbance was measured at 450 nm. \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\text{Cell viability}=[(\mathrm{As}-\mathrm{Ab})/(\mathrm{Ac}-\mathrm{Ab})]\times100\%$$\end{document} (As: absorbance of the sample wells; Ac: absorbance of the control wells; Ab: absorbance of the blank wells) (3)Cell Immunofluorescence When HK2 cells reach approximately 60% confluence, they are fixed with 4% paraformaldehyde for 15–30 min at room temperature. The cells are then washed three times with PBS and permeabilized with 0.5% Triton X-100 for 10 min, as required by the protocol, to enhance membrane permeability. To minimize non-specific binding, cells are blocked with 5% BSA for 60 min at room temperature. Primary antibodies targeting α-SMA (1:200) and Fn (1:200) are applied and incubated overnight at 4 °C. After three washes with PBS, fluorescently labeled secondary antibodies are added and incubated for 1 h at room temperature in the dark. Nuclei are stained with DAPI (1 µg/mL) for 5 min at room temperature, followed by additional PBS washes. Cells are mounted using an antifade mounting medium, and the edges of the coverslips are sealed with nail polish. Images were acquired using a fluorescence microscope (Leica DMI 3000 B, Leica, Wetzlar, Germany). (3)Cell Immunofluorescence When HK2 cells reach approximately 60% confluence, they are fixed with 4% paraformaldehyde for 15–30 min at room temperature. The cells are then washed three times with PBS and permeabilized with 0.5% Triton X-100 for 10 min, as required by the protocol, to enhance membrane permeability. To minimize non-specific binding, cells are blocked with 5% BSA for 60 min at room temperature. Primary antibodies targeting α-SMA (1:200) and Fn (1:200) are applied and incubated overnight at 4 °C. After three washes with PBS, fluorescently labeled secondary antibodies are added and incubated for 1 h at room temperature in the dark. Nuclei are stained with DAPI (1 µg/mL) for 5 min at room temperature, followed by additional PBS washes. Cells are mounted using an antifade mounting medium, and the edges of the coverslips are sealed with nail polish. Images were acquired using a fluorescence microscope (Leica DMI 3000 B, Leica, Wetzlar, Germany). Cell Immunofluorescence When HK2 cells reach approximately 60% confluence, they are fixed with 4% paraformaldehyde for 15–30 min at room temperature. The cells are then washed three times with PBS and permeabilized with 0.5% Triton X-100 for 10 min, as required by the protocol, to enhance membrane permeability. To minimize non-specific binding, cells are blocked with 5% BSA for 60 min at room temperature. Primary antibodies targeting α-SMA (1:200) and Fn (1:200) are applied and incubated overnight at 4 °C. After three washes with PBS, fluorescently labeled secondary antibodies are added and incubated for 1 h at room temperature in the dark. Nuclei are stained with DAPI (1 µg/mL) for 5 min at room temperature, followed by additional PBS washes. Cells are mounted using an antifade mounting medium, and the edges of the coverslips are sealed with nail polish. Images were acquired using a fluorescence microscope (Leica DMI 3000 B, Leica, Wetzlar, Germany). Measurement of oxidative stress markers (SOD, GSH, and MDA) SOD activity was measured via the xanthine oxidase method (A001-1–2) at 550 nm and expressed as nmol/mg protein. GSH content was determined with a colorimetric kit (A005-1–2) at 412 nm, expressed as U/mg protein. MDA levels were assessed using a TBARS assay (A003-1–2) at 532 nm. Western blot(WB) Tissue and cell lysates were prepared in RIPA buffer with protease inhibitors. Proteins were separated by SDS-PAGE and transferred to PVDF membranes, blocked with 5% milk, and incubated overnight at 4 °C with primary antibodies:α-SMA (1:2000), Collagen I (1:1000), Fn (1:1500), ACSL4 (1:5000), GPX4 (1:1000), GAPDH (Proteintech, 10494-1-AP, 1:5000). After TBST washes, membranes were incubated with HRP-conjugated secondary antibody (Proteintech, #SA00001-2, 1:4000) and visualized using ECL (Thermo Scientific, USA). Intracellular ROS detection DHE staining: Deparaffinized tissue sections were incubated with 10 µM DHE at 37 °C for 40 min in the dark, followed by PBS washes and DAPI nuclear staining for 10 min. After rinsing and drying, sections were mounted with antifade medium and imaged under a fluorescence microscope. DCFH-DA staining: HK-2 cells were incubated with DCFH-DA in serum-containing medium for 30 min at 37 °C, washed with PBS, fixed with 4% paraformaldehyde, stained with DAPI, and visualized by confocal microscopy. For quantitative analysis, cells were incubated with DCFH-DA in serum-free medium, washed, centrifuged, resuspended in PBS, and analyzed by flow cytometry. Mitochondrial superoxide detection HK-2 cells were incubated with MitoSOX™ Red in serum-free medium for 30 min at 37 °C in the dark. After three PBS washes, cells were fixed with 4% paraformaldehyde for 10 min, washed, stained with DAPI, and imaged using CLSM. For quantification, treated HK-2 cells were incubated with MitoSOX™ Red under the same conditions, washed, collected by centrifugation, resuspended in PBS, and analyzed by flow cytometry to assess mitochondrial ROS levels. JC-1 staining After treatment, HK-2 cells were washed with PBS, incubated with JC-1 working solution in culture medium at 37 °C for 20 min, and then washed twice with JC-1 buffer. Cells were collected by centrifugation, resuspended in PBS, and analyzed by flow cytometry to assess mitochondrial membrane potential (ΔΨm) depolarization. Enzyme-linked immunosorbent assay (ELISA) Levels of IL-1β, IL-6, and TNF-α in cell culture supernatants were measured using ELISA kits (R&D Systems, Minneapolis, MN, USA) according to the manufacturer’s protocol. Equal volumes of samples were added to microplate wells, and absorbance at 450 nm was recorded using a microplate reader. Cytokine concentrations were calculated based on the standard curve. Statistical analysis Statistical analysis was conducted with GraphPad Prism Version 10.0 software. One-way ANOVA with 95% confidence interval was used for calculating p values, and p < 0.05 was considered statistically significant. The sample sizes (n) were included in the figure legends. Results Synthesis and characterization of Rosi@HPDA-PEG-K3 NPs The design of Rosi@HPDA-PEG-K3 NPs is illustrated in Fig. 1A. Uniform dSiO₂ nanoparticles were first synthesized via the Stöber method and then coated with a PDA layer through dopamine self-polymerization under alkaline conditions to form dSiO₂@PDA. HF etching removed the silica core, yielding monodisperse HPDA NPs, which were subsequently loaded with Rosi and grafted with PEG-K3. TEM images showed that the resulting Rosi@HPDA-PEG-K3 NPs were quasi-spherical with a uniform size distribution (Fig. 1B). DLS analysis revealed an increase in hydrodynamic diameter from 164.6 nm (HPDA) to 178.3 nm after PEG-K3 modification, indicating successful grafting (Figure S1). Moreover, the characteristic UV absorption peaks of free PEG-NH₂ (200 nm) and K3 peptide (206 nm) in the supernatant were nearly absent, further confirming PEG-K3 conjugation (Fig. 1C–D). Fig. 1Synthesis and characterization of Rosi@HPDA-PEG-K3 NPs. (A) Representation schematic of Rosi@HPDA-PEG-K3 NPs. (B) TEM image of Rosi@HPDA-PEG-K3 NPs. (C-E) UV–vis spectra of PEG (C), K3 peptide (D), and rosiglitazone (E) in the corresponding supernatants. (F) The Zeta potentials of each group of NPs. (G) Size stability of Rosi@HPDA-PEG-K3 nanoparticles in PBS and 10% FBS over 6 days. (H) PH-dependent release profile of rosi at pH 7.4, 6.5, and 5.5. (I) The T-AOC of the Rosi@HPDA-PEG-K3 NPs at different concentrations. (J) The ability of the Rosi@HPDA-PEG-K3 NPs at various concentrations to scavenge O2•−. (K) Iron chelation efficiency of Rosi@HPDA-PEG-K3 NPs. Data are presented as mean ± SD. n = 3, ****p < 0.0001 vs. control group Synthesis and characterization of Rosi@HPDA-PEG-K3 NPs. (A) Representation schematic of Rosi@HPDA-PEG-K3 NPs. (B) TEM image of Rosi@HPDA-PEG-K3 NPs. (C-E) UV–vis spectra of PEG (C), K3 peptide (D), and rosiglitazone (E) in the corresponding supernatants. (F) The Zeta potentials of each group of NPs. (G) Size stability of Rosi@HPDA-PEG-K3 nanoparticles in PBS and 10% FBS over 6 days. (H) PH-dependent release profile of rosi at pH 7.4, 6.5, and 5.5. (I) The T-AOC of the Rosi@HPDA-PEG-K3 NPs at different concentrations. (J) The ability of the Rosi@HPDA-PEG-K3 NPs at various concentrations to scavenge O2•−. (K) Iron chelation efficiency of Rosi@HPDA-PEG-K3 NPs. Data are presented as mean ± SD. n = 3, ****p < 0.0001 vs. control group Zeta potential analysis showed that the surface potential increased from − 16 mV for HPDA NPs to − 24 mV for Rosi@HPDA-PEG-K3 NPs, indicating enhanced colloidal stability of the modified nanoparticles (Fig. 1F). To evaluate storage stability, Rosi@HPDA-PEG-K3 NPs were incubated in PBS or 10% FBS medium at 25 °C for 7 days. The particle size remained stable at ~ 170 nm over the first 6 days, with no evident aggregation or size changes, demonstrating good stability and potential for further application (Fig. 1G). The characteristic UV absorption peak of Rosi at 315 nm decreased in the supernatant after centrifugation, confirming successful drug loading (Fig. 1E). Further quantitative analysis showed that the Rosi@HPDA-PEG-K3 NPs exhibited a drug loading content (LC) of 27.7% and an encapsulation efficiency (EE) of 38.3%. We next evaluated the pH-responsive release behavior of the nanoparticles. At physiological pH (7.4), only 10.57% of Rosi was released within 24 h, whereas under acidic conditions mimicking inflammatory microenvironments (pH 6.5 and 5.5), cumulative release increased to 30% and 35.4%, respectively. This pH-sensitive release profile indicates that Rosi@HPDA-PEG-K3 NPs can achieve site-specific drug release within acidic pathological microenvironments while minimizing premature leakage in normal tissues, thereby reducing systemic toxicity (Fig. 1H). Considering the antioxidant potential of the HPDA structure due to its phenolic hydroxyl groups, we further assessed its ROS-scavenging capacity. ABTS⁺ assays showed that HPDA-PEG-K3 NPs effectively scavenged ABTS⁺ radicals in a concentration-dependent manner (Fig. 1I). Additionally, O₂•⁻ assays confirmed that notable scavenging of mitochondrial-related ROS, with an 80% reduction at 200 µg/mL, highlighting strong antioxidant activity (Fig. 1J), demonstrating their excellent antioxidant activity. Furthermore, we evaluated the iron chelation capacity of HPDA-PEG-K3 NPs using an iron assay kit. The results showed a significant decrease in free Fe²⁺ concentration with a concentration-dependent effect. Notably, the chelation efficiency of Fe²⁺ reached 46.0% after incubation with 400 mg/L HPDA-PEG-K3 NPs, indicating that HPDA-PEG-K3 NPs possess excellent iron chelation capabilities (Fig. 1K). In vivo biodistribution and biosafety assessment of Rosi@HPDA-PEG-K3 NPs To assess the targeting efficiency and biodistribution of Rosi@HPDA-PEG-K3 NPs in mice with renal interstitial fibrosis, nanoparticles were labeled with Cy5.5 and tracked using an in vivo imaging system. As shown in Fig. 2A, fluorescence predominantly accumulated in the liver within 2 h post-injection, likely due to rapid uptake by the reticuloendothelial system, while weaker signals were initially observed in the kidneys. By 24 h, hepatic fluorescence markedly decreased, accompanied by progressively increasing fluorescence intensity in the kidneys, suggesting gradual redistribution to renal tissue. Notably, Rosi@HPDA-PEG-K3 NPs exhibited significantly higher fluorescence accumulation in the kidneys than Rosi@HPDA NPs, confirming the K3 ligand-mediated renal targeting effect. In the Rosi@HPDA group, fluorescence signals within the kidneys gradually decreased and were nearly undetectable by day 7. In contrast, the Rosi@HPDA-PEG-K3 group maintained strong fluorescence in renal tissue up to day 7, and substantially declined by day 14. Quantitative analysis further confirmed that fluorescence intensity in the kidneys was consistently higher in the Rosi@HPDA-PEG-K3 group throughout the observation period (Fig. 2B). Additionally, fibrotic kidneys exhibited significantly stronger fluorescence signals than non-obstructed kidneys in both groups, probably due to UUO-induced disruption of the filtration barrier that facilitated deeper nanoparticle penetration and uptake by tubular epithelial cells (Figure 2C). Collectively, these findings highlight the superior renal targeting and prolonged retention of Rosi@HPDA-PEG-K3 NPs, particularly within diseased renal tissue. Fig. 2Biobistribution and biosafety evaluation of Rosi@HPDA-PEG-K3 NPs in mice. (A) The distribution of Rosi@HPDA-PEG NPs and Rosi@HPDA-PEG-K3 NPs in ex vivo organs. (B) Semiquantitative analysis of renal fluorescence intensity across different NPs groups. (C) Left(obstructive)-to-right(non-obstructive) kidney signal ratio. (D) H&E staining images of major organs (liver, lung, heart, spleen, and kidney) in mice at 1day, 7day, and 14 day after intravenous injection of Rosi@HPDA-PEG-K3 NPs. (E-H) Liver and renal function in mice at 1, 7, and 14 days post-injection of Rosi@HPDA-PEG-K3 NPs. Data are presented as mean ± SD. n = 5, ***p < 0.001 and ****p < 0.0001 vs control group. ns means not significant, #p < 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001 Biobistribution and biosafety evaluation of Rosi@HPDA-PEG-K3 NPs in mice. (A) The distribution of Rosi@HPDA-PEG NPs and Rosi@HPDA-PEG-K3 NPs in ex vivo organs. (B) Semiquantitative analysis of renal fluorescence intensity across different NPs groups. (C) Left(obstructive)-to-right(non-obstructive) kidney signal ratio. (D) H&E staining images of major organs (liver, lung, heart, spleen, and kidney) in mice at 1day, 7day, and 14 day after intravenous injection of Rosi@HPDA-PEG-K3 NPs. (E-H) Liver and renal function in mice at 1, 7, and 14 days post-injection of Rosi@HPDA-PEG-K3 NPs. Data are presented as mean ± SD. n = 5, ***p < 0.001 and ****p < 0.0001 vs control group. ns means not significant, #p < 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001 To evaluate the in vivo biosafety of Rosi@HPDA-PEG-K3 NPs, mice received intravenous injections of the formulation (10 mg/kg Rosi), and major organs—including the liver, lungs, heart, spleen, and kidneys—were collected on days 1, 7, and 14 post-injection. H&E staining showed intact tissue architecture without signs of inflammation, necrosis, or structural abnormalities compared to the PBS control (Fig. 2D). In parallel, serum levels of hepatic (AST, ALT) and renal (creatinine, BUN) function markers remained within normal physiological ranges (Figs. 2E–H), indicating no evident liver or kidney toxicity. Together, these findings demonstrate the favorable biocompatibility and systemic safety of Rosi@HPDA-PEG-K3 NPs in vivo. In vivo antifibrotic activity of Rosi@HPDA-PEG-K3 NPs Subsequently, the antifibrotic potential of Rosi@HPDA-PEG-K3 NPs was investigated in the UUO mouse model. As shown in Fig. 3A, H&E and Masson’s trichrome staining revealed marked tubular dilatation, epithelial atrophy, and interstitial matrix accumulation in UUO kidneys. Therapeutic intervention with Rosi, HPDA, Rosi@HPDA, and Rosi@HPDA-PEG-K3 NPs mitigated these histopathological abnormalities to varying degrees, with the Rosi@HPDA-PEG-K3 group showing the most substantial improvement. This was further supported by quantitative reductions in tubular injury scores and collagen-positive areas (Figs. 3B–C). Immunohistochemical staining further demonstrated notable downregulation of key fibrotic markers, including α-SMA and Fn, following treatment with Rosi@HPDA-PEG-K3 NPs (Fig. 3D). Consistent with these findings, Western blot analysis showed that Rosi@HPDA-PEG-K3 NPs significantly suppressed the expression of α-SMA, Fn, and Col-I, with superior efficacy compared to other treatment groups (Figs. 3E–F), demonstrating its pronounced antifibrotic efficacy in vivo. Fig. 3Effect of Rosi@HPDA-PEG-K3 NPs on renal interstitial fibrosis in vivo. (A) Comparative assessment of renal H&E and Masson’s trichrome staining among different groups, Scale bar = 100 μm. (B) Tubule atrophy score in kidney tissues. (C) Collagen positive area (%) in kidney tissues. (D) IHC evaluation of α-SMA and Fn expression in renal tissues from each group, Scale bar = 100 μm. (E) Western blot evaluation of α-SMA, Fn, and Col-I protein expression in renal tissues from each group. (F) Quantitative analysis of α-SMA, Fn, and Col-I protein. Data are presented as mean ± SD. n = 5, *p < 0.05, **p < 0.01, and ****p < 0.0001 vs. UUO group. ##p < 0.01, ####p < 0.0001 In addition, renal function analysis showed that UUO significantly elevated serum creatinine and BUN levels compared to the sham group (Figure S2). Among them, Rosi@HPDA-PEG-K3 NPs showed the most pronounced renoprotective effect, with significantly reduced serum creatinine and BUN levels. Notably, this effect was statistically superior to that of Rosi@HPDA, highlighting the therapeutic advantage conferred by K3-mediated targeting. Effect of Rosi@HPDA-PEG-K3 NPs on renal interstitial fibrosis in vivo. (A) Comparative assessment of renal H&E and Masson’s trichrome staining among different groups, Scale bar = 100 μm. (B) Tubule atrophy score in kidney tissues. (C) Collagen positive area (%) in kidney tissues. (D) IHC evaluation of α-SMA and Fn expression in renal tissues from each group, Scale bar = 100 μm. (E) Western blot evaluation of α-SMA, Fn, and Col-I protein expression in renal tissues from each group. (F) Quantitative analysis of α-SMA, Fn, and Col-I protein. Data are presented as mean ± SD. n = 5, *p < 0.05, **p < 0.01, and ****p < 0.0001 vs. UUO group. ##p < 0.01, ####p < 0.0001 In vitro antifibrotic activity of Rosi@HPDA-PEG-K3 NPs Building upon the promising antifibrotic effects observed in vivo, the biocompatibility and therapeutic potential of Rosi@HPDA-PEG-K3 NPs were further assessed in vitro. CCK-8 assays revealed negligible cytotoxicity in HK-2 cells across a concentration range of 0–200 µg/mL (based on Rosi content), confirming excellent cytocompatibility (Figure S3). Concurrently, intracellular uptake was analyzed in HK-2 cells to evaluate the cellular internalization process. Confocal microscopy showed that Rosi@HPDA-PEG-K3 NPs exhibited significantly stronger Cy5.5 fluorescence signals than Rosi@HPDA NPs at both 2 h and 6 h (Figs. 4A–B), suggesting enhanced uptake facilitated by the K3 ligand. Functionally, the expression of Fn, Col-I, and α-SMA in HK-2 cells were markedly increased in response to TGF-β1 stimulation. All nanoparticle treatments attenuated this effect, with Rosi@HPDA-PEG-K3 NPs demonstrating the most substantial suppression, as confirmed by both immunofluorescence staining and Western blot analysis (Figs. 4C–H). Together, these data confirm that Rosi@HPDA-PEG-K3 NPs possess excellent biocompatibility and exert strong antifibrotic effects in vitro, consistent with their in vivo therapeutic performance. Fig. 4Effect of Rosi@HPDA-PEG-K3 NPs on ECM accumulation in TGF-β1–stimulated HK-2 cells. (A) Confocal images showing cellular uptake of Rosi@HPDA and Rosi@HPDA-PEG-K3 NPs in HK-2 cells. (B) Quantitative fluorescence analysis of NPs uptake shown in (A). (C) Immunofluorescence staining of fibronectin (Fn) in HK-2 cells across experimental groups. Scale bar: 100 μm. (D) Quantitative fluorescence analysis of Fn. (E) Immunofluorescence staining of α-SMA in HK-2 cells. Scale bar: 100 μm. (F) Quantitative fluorescence analysis of α-SMA. (G)Western blot evaluation of α-SMA, Fn, and Col-I protein expression in HK2 from each group. (H) Quantitative analysis of α-SMA, Fn, and Col-I protein. Data are presented as mean ± SD. n = 3, **p < 0.01, ***p < 0.001, ****p < 0.0001 vs. TGF-β1 group or Rosi@HPDA NPs. ##p < 0.01, ####p < 0.0001 Effect of Rosi@HPDA-PEG-K3 NPs on ECM accumulation in TGF-β1–stimulated HK-2 cells. (A) Confocal images showing cellular uptake of Rosi@HPDA and Rosi@HPDA-PEG-K3 NPs in HK-2 cells. (B) Quantitative fluorescence analysis of NPs uptake shown in (A). (C) Immunofluorescence staining of fibronectin (Fn) in HK-2 cells across experimental groups. Scale bar: 100 μm. (D) Quantitative fluorescence analysis of Fn. (E) Immunofluorescence staining of α-SMA in HK-2 cells. Scale bar: 100 μm. (F) Quantitative fluorescence analysis of α-SMA. (G)Western blot evaluation of α-SMA, Fn, and Col-I protein expression in HK2 from each group. (H) Quantitative analysis of α-SMA, Fn, and Col-I protein. Data are presented as mean ± SD. n = 3, **p < 0.01, ***p < 0.001, ****p < 0.0001 vs. TGF-β1 group or Rosi@HPDA NPs. ##p < 0.01, ####p < 0.0001 Potential antifibrotic mechanisms of Rosi@HPDA-PEG-K3 nps: targeting ferroptosis as a central strategy Ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, is a critical trigger of TEC injury and renal interstitial fibrosis [31]. DHE staining revealed a substantial increase in renal ROS levels in the kidneys of UUO mice, while Rosi@HPDA-PEG-K3 NPs significantly reduced red fluorescence intensity, indicating enhanced ROS scavenging capacity compared to other treatments (Fig. 5A). Consistently, 4-HNE immunohistochemistry showed marked lipid peroxidation in UUO kidneys, which was effectively suppressed by Rosi@HPDA-PEG-K3 NPs (Fig. 5B). Biochemical analyses further demonstrated elevated MDA levels and depleted antioxidant markers, including SOD and GSH, in UUO kidneys. Treatment with Rosi@HPDA-PEG-K3 NPs significantly restored SOD and GSH levels and reduced MDA accumulation (Figs. 5C–E). Additionally, Rosi@HPDA-PEG-K3 NPs reduced renal Fe²⁺ content (Fig. 5F) and reversed ferroptosis-associated protein changes by downregulating ACSL4 and upregulating GPX4 expression (Figs. 5G–H). Fig. 5Effect of Rosi@HPDA-PEG-K3 NPs on ferroptosis in UUO kidneys. (A) Representative fluorescence images of ROS in renal tissues from each group. Scale bar: 100 μm. (B) Immunohistochemical staining of 4-HNE in renal tissues. Scale bar: 100 μm. (C-F) Quantification of MDA (C), SOD (D), GSH (E), and iron content (F) in renal tissues from each group. (G) Western blot analysis of GPX4 and ACSL4 expression in kidney tissues. (H) Densitometric quantification of GPX4 and ACSL4. Data are presented as mean ± SD. n = 5, *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 vs. UUO group. #p < 0.05, ##p < 0.01, ###p < 0.001, ###p < 0.0001 Effect of Rosi@HPDA-PEG-K3 NPs on ferroptosis in UUO kidneys. (A) Representative fluorescence images of ROS in renal tissues from each group. Scale bar: 100 μm. (B) Immunohistochemical staining of 4-HNE in renal tissues. Scale bar: 100 μm. (C-F) Quantification of MDA (C), SOD (D), GSH (E), and iron content (F) in renal tissues from each group. (G) Western blot analysis of GPX4 and ACSL4 expression in kidney tissues. (H) Densitometric quantification of GPX4 and ACSL4. Data are presented as mean ± SD. n = 5, *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 vs. UUO group. #p < 0.05, ##p < 0.01, ###p < 0.001, ###p < 0.0001 To validate the in vivo findings, ferroptosis-associated oxidative stress was further examined in TGF-β1-stimulated HK-2 cells. DCFH-DA staining and flow cytometry revealed that all nanoparticle formulations mitigated ROS accumulation to varying degrees, with Rosi@HPDA-PEG-K3 NPs showing the strongest inhibitory effect (Fig. 6A-C). Consistently, CCK-8 analysis demonstrated that Rosi@HPDA-PEG-K3 NPs markedly improved cell viability compromised by TGF-β1 stimulation, further confirming their cytoprotective effect against ferroptotic injury (Fig. 6D). Correspondingly, Rosi@HPDA-PEG-K3 NPs significantly attenuated lipid peroxidation, as evidenced by decreased MDA levels, and restored antioxidant enzyme activities, including SOD and GSH (Figs. 6E–G). Parallel assessment of ferroptosis-related markers revealed that Rosi@HPDA-PEG-K3 NPs reduced intracellular Fe²⁺ levels (Fig. 6H), downregulated ACSL4, and upregulated GPX4 expression (Figs. 6I–J), indicating effective suppression of ferroptotic signaling in vitro. Fig. 6Effect of Rosi@HPDA-PEG-K3 NPs on ferroptosis in TGF-β1–stimulated HK-2 cells. (A) Representative fluorescence images of intracellular ROS in each group. (B) Flow cytometry profiles of ROS levels in HK-2 cells. (C) Quantitative fluorescence analysis of ROS intensity. (D) CCK-8 assay evaluating HK-2 cell viability. (E–H) Quantification of MDA (E), SOD (F), GSH (G), and intracellular iron levels(H)in each group. (I) Western blot analysis of GPX4 and ACSL4 protein expression. (J) Densitometric quantification of GPX4 and ACSL4. n = 3, Data are presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 vs. TGF-β1 group. #p < 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001. Effect of Rosi@HPDA-PEG-K3 NPs on ferroptosis in TGF-β1–stimulated HK-2 cells. (A) Representative fluorescence images of intracellular ROS in each group. (B) Flow cytometry profiles of ROS levels in HK-2 cells. (C) Quantitative fluorescence analysis of ROS intensity. (D) CCK-8 assay evaluating HK-2 cell viability. (E–H) Quantification of MDA (E), SOD (F), GSH (G), and intracellular iron levels(H)in each group. (I) Western blot analysis of GPX4 and ACSL4 protein expression. (J) Densitometric quantification of GPX4 and ACSL4. n = 3, Data are presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 vs. TGF-β1 group. #p < 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001. In summary, Rosi@HPDA-PEG-K3 NPs mitigate ferroptosis by restoring iron homeostasis, attenuating lipid peroxidation, and enhancing antioxidant defenses through coordinated modulation of ferroptosis-associated pathways, thereby providing mechanistic support for their antifibrotic effects. Rosi@HPDA-PEG-K3 NPs alleviate mitochondrial oxidative stress and downregulate inflammatory signaling Ferroptosis-induced mitochondrial dysfunction—characterized by elevated mitochondrial ROS and impaired membrane potential—can further aggravate oxidative stress, establishing a detrimental feedback loop [32]. To confirm whether Rosi@HPDA-PEG-K3 NPs provide mitochondrial protection in addition to ferroptosis inhibition, we assessed MitoSOX and membrane potential (MMP) in TGF-β1-stimulated HK-2 cells. MitoSOX staining and flow cytometry revealed that TGF-β1 markedly increased mitochondrial ROS, whereas Rosi@HPDA-PEG-K3 NPs treatment resulted in a pronounced suppression of this increase, outperforming other treatment groups (Figs. 7A–C). In parallel, JC-1 staining showed that TGF-β1 induced a substantial loss of MMP, reflected by an increased percentage of cells with low MMP (Fig. 7D-E). Rosi@HPDA-PEG-K3 NPs restored MMP to near-baseline levels, with only 5.8% of cells exhibiting MMP loss—significantly lower than the Rosi (37.3%), HPDA (35.2%), and Rosi@HPDA (11.8%) groups (Figs. 7D–E). Fig. 7Effect of Rosi@HPDA-PEG-K3 NPs on mitochondrial dysfunction and inflammation in HK-2 cells. (A) Representative fluorescence images of mitochondrial ROS (MitoSOX) in each group. Scale bar: 100 μm.(B) Quantitative analysis of MitoSOX fluorescence intensity. (C) Flow cytometry profiles of MitoSOX levels in HK-2 cells. (D) Quantification of mitochondrial membrane potential (MMP) loss by JC-1 staining. (E) Flow cytometry plots of JC-1 aggregates/monomers demonstrating MMP depolarization. (F–H) ELISA quantification of IL-1β (F), TNF-α (G), and IL-6 (H) levels in HK-2 cells. Data are presented as mean ± SD. **p < 0.01, ***p < 0.001, and ****p < 0.0001 vs. TGF-β1 group. ###p < 0.001, ####p < 0.0001 Effect of Rosi@HPDA-PEG-K3 NPs on mitochondrial dysfunction and inflammation in HK-2 cells. (A) Representative fluorescence images of mitochondrial ROS (MitoSOX) in each group. Scale bar: 100 μm.(B) Quantitative analysis of MitoSOX fluorescence intensity. (C) Flow cytometry profiles of MitoSOX levels in HK-2 cells. (D) Quantification of mitochondrial membrane potential (MMP) loss by JC-1 staining. (E) Flow cytometry plots of JC-1 aggregates/monomers demonstrating MMP depolarization. (F–H) ELISA quantification of IL-1β (F), TNF-α (G), and IL-6 (H) levels in HK-2 cells. Data are presented as mean ± SD. **p < 0.01, ***p < 0.001, and ****p < 0.0001 vs. TGF-β1 group. ###p < 0.001, ####p < 0.0001 Based on the central role of mitochondrial ROS in activating the NLRP3 inflammasome, we further examined proinflammatory cytokine expression [33]. TGF-β1 markedly upregulated IL-1β, TNF-α, and IL-6 levels, which were progressively suppressed by Rosi, HPDA, and Rosi@HPDA. Importantly, Rosi@HPDA-PEG-K3 NPs exhibited the most potent anti-inflammatory effect across all markers (Figs. 7F–H). These results demonstrate the ability of Rosi@HPDA-PEG-K3 NPs to effectively interrupt the amplification cascade of oxidative stress, mitochondrial damage, and inflammatory response. Discussion Renal interstitial fibrosis is a core pathological event driving the irreversible progression of CKD toward ESRD. A large body of evidence suggests that the TECs, as initiators of inflammatory amplification and stromal remodeling, play a central regulatory role in the onset and propagation of fibrosis [3]. Achieving precise protection and functional restoration of this cell type remains a major challenge in the field of precision therapy for CKD. In recent years, ferroptosis—a novel form of programmed cell death characterized by iron dependence and lipid peroxidation—has emerged as a key mechanism in tubular injury and fibrotic progression, and has become a research hotspot in the field of kidney disease research [8, 34]. Studies have shown that modulation of ferroptosis can effectively attenuate renal interstitial fibrosis in various models. Ferroptosis inhibitors, such as Ferrostatin-1 and Deferoxamine, transiently ameliorate kidney tissue injury; however, their limited targeting ability, low bioavailability, and narrow mechanistic coverage hinder sustained, efficient, and precise intervention [35–37]. To address these limitations, this study designed and constructed Rosi@HPDA-PEG-K3 NPs, combining ferroptosis inhibition, antioxidation, targeted delivery, and pH-responsive drug release. Comprehensive in vitro and in vivo evaluations demonstrated that this platform significantly enhanced therapeutic efficacy, minimized systemic toxicity, and ameliorated renal interstitial fibrosis through coordinated modulation of ferroptosis, oxidative stress, and inflammation. Rosi, a classical PPAR-γ agonist, has recently been found to inhibit ferroptosis by targeting ACSL4 [38, 39]. However, its clinical use is hindered by poor aqueous solubility, broad systemic distribution, short half-life, low bioavailability, and cardiovascular risks [19]. Thus, there is an urgent need to develop optimized drug delivery strategies to enhance the pharmacokinetic profile and safety of Rosi. Previous studies have explored nanocarriers such as poly(lactic-co-glycolic acid) (PLGA), metal-organic frameworks (MOFs), and liposomes for renal applications [40–42]. However, these systems are often hindered by poor targeting, structural instability, and uncontrolled release, limiting their translational potential [43–45]. To overcome these challenges, we developed a hollow polydopamine-based nanoplatform, Rosi@HPDA-PEG-K3, that integrates multiple synergistic features for renal-targeted therapy. our system leveraged the hollow structure of HPDA for efficient Rosi encapsulation and employed a K3 peptide for selective TEC targeting. PEGylation further improved circulation stability. This approach enabled efficient accumulation and prolonged retention of the drug in lesion areas. Biodistribution and confocal microscopy confirmed selective renal accumulation and effective delivery to fibrotic tissue. Additionally, the pH-sensitive release behavior enabled site-specific drug liberation in the acidic microenvironment of fibrosis while limiting off-target leakage, enhancing therapeutic precision. Meanwhile, cytotoxicity and histological assessments confirmed the favorable biosafety profile of the nanosystem. This multistage regulatory strategy significantly enhanced delivery efficiency and tissue selectivity, overcoming the challenge of non-specific distribution and diluted efficacy associated with conventional small-molecule drugs, and providing a more precise nanotherapeutic strategy for kidney-targeted treatment. Consistent with the study’s conceptual framework, our primary aim was to establish a proof-of-concept that conjugating Rosi to an HPDA-PEG-K3 nanoplatform enhances tubular targeting and minimizes off-target toxicity, rather than demonstrating efficacy across all CKD etiologies. We therefore selected the UUO model as a classical, reproducible fibrosis system in which ferroptosis plays a key pathogenic role, and inhibition of ferroptosis has been shown to attenuate renal injury. Within this validated context, Rosi@HPDA-PEG-K3 provided a rigorous and representative platform to investigate mechanism and therapeutic performance. Mechanistically, compared with previous approaches using free Rosi, iron chelators (e.g., DFO), or radical scavengers (e.g., Fer-1) [46], Rosi@HPDA-PEG-K3 NPs achieve more profound integration of multiple mechanism. On the one hand, Rosi@HPDA-PEG-K3 NPs suppressed ferroptosis by downregulating ACSL4, upregulating GPX4, and reducing lipid peroxidation markers (MDA, 4-HNE). On the other hand, the intrinsic Fe²⁺ chelation and radical scavenging properties of HPDA synergized with Rosi to amplify antioxidative capacity. Furthermore, the nanocarrier preserved mitochondrial function, as evidenced by reduced mitochondrial ROS and restored membrane potential (MMP), effectively interrupting the oxidative stress–mitochondrial dysfunction–inflammation axis. Consistently, Rosi@HPDA-PEG-K3 NPs downregulated IL-1β, TNF-α, and IL-6, underscoring their anti-inflammatory potential in CKD. Nevertheless, this study has several limitations that should be acknowledged. First, although the UUO model is well-established for investigating renal fibrosis, it does not fully replicate the complex, multifactorial, and slowly progressive pathophysiology of CKD. While our data support the direct anti-fibrotic activity of Rosi@HPDA-PEG-K3 NPs, their long-term efficacy in chronic and progressive forms of CKD, such as streptozotocin-induced diabetic nephropathy, adenine-induced CKD, and 5/6 nephrectomy, remains to be further defined in future studies. Second, although the short-term outcomes are encouraging, the long-term safety and efficacy profile of our nanoplatform requires further comprehensive evaluation. Subsequent research will specifically focus on assessing chronic toxicity and therapeutic durability in both UUO and diabetic nephropathy models—an essential step toward clinical translation. At the mechanistic level, systems-scale transcriptomic and lipidomic analyses will be pursued to delineate effects on iron handling and metabolic reprogramming. Finally, validation in clinical specimens and translational studies will be essential. Taken together, efficacy and safety in this well-accepted UUO model support the platform’s potential and hypothesize broader applicability to other CKD contexts—a proposition we will test explicitly in future work. Conclusion In summary, Rosi@HPDA-PEG-K3 NPs deliver Rosi specifically to renal TECs and exert therapeutic effects through the integration of ferroptosis inhibition, mitochondrial protection, and inflammation modulation. This multifaceted mechanism significantly mitigates the pathological progression of renal interstitial fibrosis, demonstrating robust therapeutic efficacy and favorable biocompatibility. This study not only deepens theoretical insights into ferroptosis regulation in renal fibrosis, but also establishes a nanodrug delivery system with targeting ability, therapeutic efficacy, and controlled release capabilities, highlighting its considerable scientific value and the translational potential. Supplementary Information Supplementary Material 1. Supplementary Material 1. Supplementary Material 2. Supplementary Material 2. Supplementary Material 3. Supplementary Material 3. Supplementary Material 4. Supplementary Material 4.